Logo-bi
Bioimpacts. 2019;9(1): 45-56. doi: 10.15171/bi.2019.06
PMID: 30788259        PMCID: PMC6378095

Original Research

In silico design of a triple-negative breast cancer vaccine by targeting cancer testis antigens

Sepideh Parvizpour 1, Jafar Razmara 2, Mohammad M. Pourseif 1, Yadollah Omidi 1,3 * ORCID

Cited by CrossRef: 22

1- Deb D, Basak S, Kar T, Narsaria U, Castiglione F, Paul A, Pandey A, Srivastava A. Immunoinformatics based designing a multi‐epitope vaccine against pathogenic Chandipura vesiculovirus. J of Cellular Biochemistry. 2022;123(2):322 [Crossref]
2- Masoudi-Sobhanzadeh Y, Jafari B, Parvizpour S, Pourseif M, Omidi Y. A novel multi-objective metaheuristic algorithm for protein-peptide docking and benchmarking on the LEADS-PEP dataset. Computers in Biology and Medicine. 2021;138:104896 [Crossref]
3- Kardani K, Bolhassani A, Namvar A. An overview ofin silicovaccine design against different pathogens and cancer. Expert Review of Vaccines. 2020;19(8):699 [Crossref]
4- Putting into Perspective the Future of Cancer Vaccines: Targeted Immunotherapy. EMJ. 2020; [Crossref]
5- Paranthaman P, Veerappapillai S. Tackling suppressive cancer microenvironment by NARF-derived immune modulatory vaccine and its validation using simulation strategies. Front Phys. 2024;12 [Crossref]
6- Deyhimfar R, Izady M, Shoghi M, Kazazi M, Ghazvini Z, Nazari H, Fekrirad Z, Arefian E. The clinical impact of mRNA therapeutics in the treatment of cancers, infections, genetic disorders, and autoimmune diseases. Heliyon. 2024;10(5):e26971 [Crossref]
7- Liu W, Tang H, Li L, Wang X, Yu Z, Li J. Peptide‐based therapeutic cancer vaccine: Current trends in clinical application. Cell Proliferation. 2021;54(5) [Crossref]
8- Mohammadzadeh R, Soleimanpour S, Pishdadian A, Farsiani H. Designing and development of epitope-based vaccines againstHelicobacter pylori. Critical Reviews in Microbiology. 2022;48(4):489 [Crossref]
9- Omidi Y, Mobasher M, Castejon A, Mahmoudi M. Recent advances in nanoscale targeted therapy of HER2-positive breast cancer. Journal of Drug Targeting. 2022;30(7):687 [Crossref]
10- Dar M, Kumar P, Kumar P, Shrivastava A, Dar M, Chauhan R, Trivedi V, Singh A, Khan E, Velayutham R, Dhingra S. Designing of Peptide Based Multi-Epitope Vaccine Construct against Gallbladder Cancer Using Immunoinformatics and Computational Approaches. Vaccines. 2022;10(11):1850 [Crossref]
11- Rajendran Krishnamoorthy H, Karuppasamy R. Designing a novel SOX9 based multi-epitope vaccine to combat metastatic triple-negative breast cancer using immunoinformatics approach. Mol Divers. 2023;27(4):1829 [Crossref]
12- Zare H, Bakherad H, Esfahani A, Aghamollaei H, Gargari S, Aliomrani M, Ebrahimizadeh W. Investigating the effect of cGRP78 vaccine against different cancer cells and its role in reducing melanoma metastasis. 2024;19(1):73 [Crossref]
13- Ma M, Liu J, Jin S, Wang L. Development of tumour peptide vaccines: From universalization to personalization. Scand J Immunol. 2020;91(6) [Crossref]
14- Parvizpour S, Pourseif M, Razmara J, Rafi M, Omidi Y. Epitope-based vaccine design: a comprehensive overview of bioinformatics approaches. Drug Discovery Today. 2020;25(6):1034 [Crossref]
15- Fan C, Qu H, Wang X, Sobhani N, Wang L, Liu S, Xiong W, Zeng Z, Li Y. Cancer/testis antigens: from serology to mRNA cancer vaccine. Seminars in Cancer Biology. 2021;76:218 [Crossref]
16- See S, Smith S, Finkelman B, LaBoy C, Novo J, Siziopikou K, Blanco L. The role of PRAME and NY-ESO-1 as potential therapeutic and prognostic biomarkers in triple-negative breast carcinomas. Pathology - Research and Practice. 2023;241:154299 [Crossref]
17- Paranthaman P, Veerappapillai S. Design of a potential Sema4A-based multi-epitope vaccine to combat triple-negative breast cancer: an immunoinformatic approach. Med Oncol. 2023;40(3) [Crossref]
18- Pourseif M, Yousefpour M, Aminianfar M, Moghaddam G, Nematollahi A. A multi-method and structure-based in silico vaccine designing against Echinococcus granulosus through investigating enolase protein. Bioimpacts. 2019;9(3):131 [Crossref]
19- Nelde A, Rammensee H, Walz J. The Peptide Vaccine of the Future. Molecular & Cellular Proteomics. 2021;20:100022 [Crossref]
20- Parvizpour S, Masoudi-Sobhanzadeh Y, Pourseif M, Barzegari A, Razmara J, Omidi Y. Pharmacoinformatics-based phytochemical screening for anticancer impacts of yellow sweet clover, Melilotus officinalis (Linn.) Pall. Computers in Biology and Medicine. 2021;138:104921 [Crossref]
21- Salehi M, Razmara J, Lotfi S, Mahan F. A One-Dimensional Probabilistic Convolutional Neural Network for Prediction of Breast Cancer Survivability. 2021; [Crossref]
22- Zhan C, Ding D, Zhang W, Wang H, Mao Z, Liu G. The cancer-testis antigen a-kinase anchor protein 3 facilitates breast cancer progression via activation of the PTEN/PI3K/AKT/mTOR signaling. Bioengineered. 2022;13(4):8478 [Crossref]
23- Farnudian-Habibi A, Mirjani M, Montazeri V, Aliebrahimi S, Katouzian I, Abdolhosseini S, Rahmani A, Keyvani H, Ostad S, Rad-Malekshahi M. Review on Approved and Inprogress COVID-19 Vaccines. Iran J Pharm Res. 2022;21(1) [Crossref]
24- Sadr S, Borji H. Echinococcus granulosus as a Promising Therapeutic Agent against Triplenegative Breast Cancer. CCTR. 2023;19(4):292 [Crossref]
25- Passaro A, Al Bakir M, Hamilton E, Diehn M, André F, Roy-Chowdhuri S, Mountzios G, Wistuba I, Swanton C, Peters S. Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. Cell. 2024;187(7):1617 [Crossref]
26- Parvizpour S, Elengoe A, Alizadeh E, Razmara J, Shamsir M. In silico targeting breast cancer biomarkers by applying rambutan ( Nephelium lappaceum) phytocompounds . Journal of Biomolecular Structure and Dynamics. 2023;41(19):10037 [Crossref]

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge